2022
Clinical cancer research

Praluzatamab ravtansine, a CD166-Targeting antibody–drug conjugate, in patients with advanced solid tumors: an open-label phase I/II trial

Details

Authors:
Valentina Boni, Olga Vasiljeva
Title of the Article:
Praluzatamab ravtansine, a CD166-Targeting antibody–drug conjugate, in patients with advanced solid tumors: an open-label phase I/II trial
Journal:
Clinical cancer research
Year of Publication:
2022
Pages:
2020-2029
Volume and Issue Number:
vol. 28, no. 10
ISSN Number:
1078-0432
DOI (Digital Object Identifier):
10.1158/1078-0432.CCR-21-3656
COBISS ID:
113598979
COBISS
Researchers

Researchers

Meet our dedicated researchers behind this publication:

References

References & Citations

Upload File Icon - Laboratory X Webflow Template

Access paper

Lorem ipsum dolor sit amet consectetur vel nunc platea orci quis dolor ac.

More documentation

Explore our collection of 200+ Premium Webflow Templates